GSK3685032 is a potent first-in-class DNMT1-selective inhibitor. GSK3685032 induces robust loss of DNA methylation, transcriptional activation and cancer cell growth inhibition in vitro. Due to improved in vivo tolerability compared with decitabine, GSK3685032 yields superior tumor regression and survival mouse models of acute myeloid leukemia.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Related DNA Methyltransferase Products|
Bobcat339 is a novel cytosine-based TET enzyme inhibitor with IC50s of 33 and 73 uM for TET1/2, it does not inhibit the DNA methyltransferase DNMT3a.
DC_05 is a potent and selective non-nucleoside DNMT1 (DNA methyltransferase 1) inhibitor that significantly inhibits cancer cell proliferation.
Vitamin D2 is a selective inhibitor of mammalian DNA polymerase A (pol A) with IC50 of 123 mM.
SGI-1027 is a DNMT inhibitor with IC50 of 6, 8, 7.5 μM for DNMT1, DNMT3A, and DNMT3B
RG108 is a novel small-molecule inhibitors of DNA methyltransferases with IC50 of 115 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.